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Summary
 
We have recently described a system for the generation of dendritic cells (DC) and Langerhans
cells (LC) from defined CD34
 
1
 
 precursors purified from peripheral blood of healthy adult vol-
unteers (1). This study has now been extended by the characterization of two distinct subpop-
ulations of CD34
 
1
 
 cells in normal human peripheral blood as defined by the expression of the
skin homing receptor cutaneous lymphocyte-associated antigen (CLA). CD34
 
1
 
/CLA
 
1
 
 cells
from normal peripheral blood were found to be CD71
 
LOW
 
/CD11a
 
1
 
/CD11b
 
1
 
/CD49d
 
1
 
/
CD45RA
 
1
 
 whereas CD34
 
1
 
/CLA
 
2
 
 cells displayed the CD71
 
1
 
/CD11a
 
LOW
 
/CD11b
 
LOW
 
/CD49d
 
(
 
1
 
)
 
/
CD45RA
 
LOW
 
 phenotype. To determine the differentiation pathways of these two cell popula-
tions, CD34
 
1
 
 cells were sorted into CLA
 
1
 
 and CLA
 
2
 
 fractions, stimulated with GM-CSF and
TNF-
 
a
 
 in vitro, and then were cultured for 10 to 18 d. Similar to unfractionated CD34
 
1
 
 cells,
the progeny of both cell populations contained sizable numbers (12–22%) of dendritically
shaped, CD1a
 
1
 
/HLA-DR
 
111
 
 cells. In addition to differences in their motility, the two den-
dritic cell populations generated differed from each other by the expression of LC-specific
structures. Only the precursors expressing the skin homing receptor were found to differentiate
into LC as evidenced by the presence of Birbeck granules. In contrast, CLA
 
2
 
 precursor cells
generated a CD1a
 
1
 
 DC population devoid of Birbeck granule–containing LC. Provided that
comparable mechanisms as found in this study are also operative in vivo, we postulate that the
topographic organization of the DC system is already determined, at least in part, at the pro-
genitor level.
 
D
 
endritic cells (DC) are bone marrow–derived leuko-
cytes with potent immunostimulatory properties. They
occur in small numbers in most non-lymphoid tissues and
are well equipped to take up various types of antigen. After an
antigenic challenge, these cells undergo phenotypic changes
that allow them to leave their residence, to migrate to the
regional lymphoid organs, and, upon arrival in the T-depen-
dent zones, to activate resting T cells (2). This is best ex-
emplified by the antigen-induced metamorphosis of epi-
dermal Langerhans cells (LC; CD45
 
1
 
/CD1a
 
1
 
/CD32
 
1
 
/
E-cadherin
 
1
 
/Birbeck granule
 
1
 
/ATPase
 
1
 
/MHC class I
 
1
 
and II
 
1
 
) into interdigitating reticulum cells (CD45
 
1
 
/CD1a
 
2
 
/
CD32
 
2
 
/E-cadherin
 
2
 
/Birbeck granule
 
2
 
/ATPase
 
2
 
/MHC
class I
 
11
 
 and II
 
111
 
) (3, 4). In contrast to the substantial in-
formation about the factors governing DC trafficking from
the periphery to the lymphoid organs, relatively little is
known about the reverse process, e.g., about the mecha-
nisms underlying the immigration of circulating LC pre-
cursors in their ultimate tissue of residence, i.e., the skin
and epidermis.
Together with the findings that the HECA-452–defined
E-selectin ligand cutaneous lymphocyte-associated antigen
(CLA) functions as a skin homing molecule for certain
memory T cells (5), that LC within the skin are CLA
 
1
 
 (6),
and that intravenously injected LC specifically home to the
skin (7), our recent observation that approximately half of
the CD34
 
1
 
 hematopoietic progenitor cells circulating in
the peripheral blood of healthy adults (PBPC) react with
the mAb HECA-452 (1) led us to the hypothesis that CLA
might also be involved in the migration and/or the matura-
tion of LC precursors. Here, we provide evidence that cir-
culating CD34
 
1
 
/CLA
 
1
 
 but not CD34
 
1
 
/CLA
 
2
 
 PBPC can
differentiate into LC in vitro.
 
A preliminary report on this work was presented at the 4th International
Symposium on Dendritic Cells in Fundamental and Clinical Immunol-
ogy; Lido, Venice, October 5–10, 1996.
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Materials and Methods 
 
Purification of CD34
 
1
 
 PBPC from Healthy Volunteers.
 
CD34
 
1
 
PBPC were isolated essentially as described (1). Following this
procedure, 2 
 
3
 
 10
 
6
 
 CD34
 
1
 
 PBPC with a purity of 
 
.
 
95% and a
viability of 
 
.
 
96% can be reproducibly procured from one leuka-
pheresis product (1.5–3 
 
3
 
 10
 
9
 
 PBMC) (1).
 
Three-Color Flow Cytometry of PBPC.
 
Freshly isolated PBPC
were adjusted to 5 
 
3
 
 10
 
5
 
 cells/ml in PBS containing 1% FCS and
0.1% NaN
 
3
 
 and quenched with normal sheep serum (10% vol/
vol, 30 min on ice) to reduce nonspecific reactivity. Cells were
reacted for 30 min on ice with a panel of mouse mAbs against hu-
man leukocyte differentiation antigens including CD45RA (clone
2H4; Coulter, Hialeah, FL), CD71 and HLA-DR (clones LO1.1
and L243; Becton Dickinson Immunocytometry Systems, BD-IS,
San Jose, CA), CD11a, CD11b, CD18, CD49d, CD49e, CD29
(clones 25.3, Bear 1, BL5, HP2.1, SAM1, K20; all Immunotech,
Marseille, France) as well as two different anti-CD1a mAb, which
also served as isotype controls (clone OKT6, mouse IgG1; Ortho,
Raritan, NJ, and B17.20.9, mouse IgG2a; Immunotech). With
washings after each incubation, cells were consecutively exposed to
biotinylated F(ab
 
9
 
)
 
2
 
 fragments of a polyclonal sheep anti–mouse
Ig (10 min, on ice; Amersham Inc., Arlington Heights, IL), nor-
mal mouse serum (10% vol/vol, 20 min, on ice) and, finally,
streptavidin-PerCP (BD-IS) simultaneously with mouse anti–human
CD34-PE (8G12-PE; BD-IS) and HECA-452-FITC (5) (kindly
provided by Dr. L. Picker, University of Texas Southwestern
Medical Center, Dallas, TX) or the respective isotype control mAbs
(30 min, on ice). For data analysis, CLA
 
1
 
/CD34
 
1
 
 and CLA
 
2
 
/
CD34
 
1
 
 events were gated and reactivity with the third mAb was
measured as mean fluorescence intensity using a FACScan
 
Ò
 
 flow
cytometer (BD-IS) equipped with Lysys
 
Ô
 
 II (BD-IS) software.
 
Suspension Culture of PBPC Subpopulations.
 
To separate CLA
 
1
 
/
CD34
 
1
 
 from CLA
 
2
 
/CD34
 
1
 
 cells, 24-well cell culture plates (Cos-
tar, Cambridge, MA) were coated with purified HECA-452 mAb
(10 
 
m
 
g/ml, overnight, 4
 
8
 
C) and then extensively washed with PBS.
Freshly isolated CD34
 
1
 
 PBPC were incubated in HECA-452–
coated wells for 60 min at 37
 
8
 
C (10
 
5
 
 cells/well). Thereafter,
plates were rinsed 3
 
3
 
 with 1 ml HBSS to collect the nonadher-
ent cell population.
Both the adherent and nonadherent PBPC populations were
cultured in RPMI 1640 containing 2 mM 
 
l
 
-glutamine, 0.1 mM
nonessential amino acids, 100 U/ml penicillin, and 100 
 
m
 
g/ml strep-
tomycin (all GIBCO BRL, Gaithersburg, MD; complete me-
dium) supplemented with 20% heat-inactivated FCS, 200 U/ml
recombinant human GM-CSF (kindly provided by Sandoz AG,
Basle, Switzerland), and 50 U/ml TNF-
 
a
 
 (Genzyme, Cam-
bridge, MA). Alternatively, aliquots of unfractionated freshly iso-
lated PBPC were cultured at 5–7 
 
3
 
 10
 
4
 
 cells/ml in the same me-
dium in 24-well culture plates, which were either coated with the
HECA-452 mAb as described above or mock (HBSS)-coated.
Cultures were maintained for at least 3 wk (37
 
8
 
C, humidified at-
mosphere, 5% CO
 
2
 
) by replacing one-fourth of the medium with
fresh cytokine-supplemented complete medium every 4–5 d.
During the daily routine inspection of the cultures, we ob-
served differences in the motility of cells derived from the two
PBPC populations and used time lapse microphotography (Axio-
vert 135 equipped with a Contax 167MT camera; Zeiss, Ober-
kochen, Germany) to document these differences.
 
Phenotypic Analysis of PBPC-derived Cells by Immunocytochemis-
try, Flow Cytometry, and Electron Microscopy.
 
Cells derived from
unfractionated PBPC or the HECA-452–sorted subpopulations
were harvested after defined periods of culture with GM-CSF/
TNF-
 
a
 
 (10, 14, 16, 18 d) and subjected to immunohistochemis-
try, flow cytometry, and immuno-electron microscopy.
For immunohistochemistry, cells were placed onto adhesion
slides (Bio-Rad, Richmond, CA), allowed to attach for 10 min at
room temperature (RT), fixed with methanol (15 min, 
 
2
 
20
 
8
 
C),
and, after quenching with normal goat serum (1% vol/vol in
PBS, with 1% H
 
2
 
O
 
2
 
 to exhaust endogenous peroxidase; 30 min,
4
 
8
 
C), coincubated overnight at 4
 
8
 
C in a humidified chamber with
the mAb Lag (mouse IgG1, directed against LC-associated Bir-
beck granules; kindly provided by Dr. S. Imamura [8]) and anti-
CD1a (clone B17.20.9, mouse IgG2a; Immunotech) or with the
appropriate isotype controls. The specimens were then reacted si-
multaneously with goat anti–mouse IgG1 and biotinylated goat
anti–mouse IgG2a (30 min, RT; both Southern Biotechnology
Associates Inc., Birmingham, AL). IgG1-binding was visualized in
red using mouse alkaline phosphatase–anti-alkaline phosphatase
(APAAP, 30 min, RT; Dakopatts A/S, Glostrup, Denmark) with
Fast Red (Sigma) as the developing reagent followed by visualiza-
tion of IgG2a reactivity in brown with StreptABComplex/HRP
(30 min, RT; Dakopatts) and diaminobenzidine (Sigma) accord-
ing to previously published procedures (1, 6).
For additional flow cytometric analyses, PBPC-derived cells
were labeled with anti-human CD1a-PE (clone SFCI19Thy1A8,
T6RD1; Coulter), and counterstained with either mouse anti–
human CD14-FITC (clone MEM 18; An der Grub, Kaumberg,
Austria), mouse anti–human HLA-DR (clone L243, BD-IS) or
mouse anti–human CD80 (clone BB1B7, BD-IS) plus biotiny-
lated F(ab
 
9
 
)
 
2
 
 sheep anti–mouse Ig (Amersham) and then subjected
to streptavidin–PerCP (BD-IS).
For immunoelectron microscopic analysis, PBPC-derived cells
were reacted with mouse anti–human CD1a (BL6; Immunotech)
or mouse IgG1 isotype control mAbs in the presence of normal
goat serum (30 min, 4
 
8
 
C; British BioCell Laboratories, Cardiff,
UK). After two washes at 4
 
8
 
C, they were incubated with gold-
labeled (10 nm) goat anti–mouse Ab (30 min, 4
 
8
 
C; BioCell),
fixed for 60 min at 4
 
8
 
C in 3% glutaraldehyde (Electron Micros-
copy Sciences, Euromedex, Strasbourg, France) in 0.1 M sodium
cacodylate buffer containing 2% sucrose (pH 7.3; both Merck,
Darmstadt, Germany) and for 45 min at 4
 
8
 
C in 1.5% glutaralde-
hyde. Cells were then incubated in 1% tannic acid (Merck) in
0.05 M sodium cacodylate buffer (45 min, RT), postfixed in 2%
osmium tetroxide (Merck) in 0.1 M sodium cacodylate buffer (1 h,
RT), dehydrated in a graded series of ethanol (50, 70, 80, 95,
100%), incubated overnight in Epon (Electron Microscopy Sci-
ences)-absolute alcohol (1:1 vol/vol), and finally embedded in
Epon. Ultrathin sections, stained with lead citrate (Leica, Bron,
France) and uranyl acetate (Merck), were examined under a Phil-
ips CM 120 BioTwin electron microscope (120 kV).
 
Allogeneic Mixed Leukocyte Reaction.
 
Allogeneic mixed leuko-
cyte reactions (MLR) were performed to test for the presence of
potent accessory cells within the populations of PBPC-derived cells.
Various numbers of mitomycin C (50 
 
m
 
g/ml, 30 min, 37
 
8
 
C; Sigma
Chem. Co., St. Louis, MO)–treated PBPC-derived cells and, for
control purposes, plastic-adherent monocytes from the same indi-
vidual were cocultured with 10
 
5
 
 purified allogeneic T cells in
complete medium supplemented with 10% plasma of PBPC do-
nor origin in 96-well round-bottomed culture plates (Costar).
MLRs were maintained for 4, 5, or 6 d (37
 
8
 
C, humidified atmo-
sphere, 5% CO
 
2
 
) before [3H]thymidine (1 mCi/well; Amersham)
was added for additional 16 h. Incorporation of the radionucleotide
was measured with a b-scintillation spectroscope (Packard Instru-1133 Strunk et al. Brief Definitive Report
ments, Meriden, CT). Results are expressed as mean cpm SD of
triplicate cultures. Proliferation of 105 T cells or mitomycin
C–treated stimulators alone resulted in an incorporation rate of
,500 cpm.
Results and Discussion
Distinct Phenotype of CLA1 and CLA2 PBPC. In a first
series of experiments, we used three-color flow cytometry
to determine the immunophenotype of HECA-452–reac-
tive and HECA-nonreactive CD341 PBPC. We found that
both populations were CD1a2, expressed equal levels of
HLA-DR and common CD45 molecules, but exhibited pro-
nounced quantitative and qualitative differences in their dis-
tribution of various leukocyte differentiation antigens. Quan-
titatively, CLA1/CD341 cells showed a three- to fivefold
higher expression of the b2-integrins LFA-1 (CD11a/CD18)
and Mac-1/C3bi (CD11b/CD18), and a 1.5-fold higher
expression of the b1-integrins VLA-4 (CD49d/CD29) and
VLA-5 (CD49e/CD29) as compared with CLA2/CD341
cells (Fig. 1). It will be interesting to determine whether
the higher level of LFA-1/VLA-4 expression on CLA1/
CD341 PBPC also allows for a more efficient binding to
VCAM-11/E-selectin1 endothelia (5, 9).
Qualitatively, the major phenotypic differences between
the two progenitor cell populations are the almost selective
anti-CD45RA reactivity of CLA1 PBPC and the eightfold
higher transferrin receptor (CD71) expression on CLA2/
CD45RA2 PBPC (Fig. 1). Since CD45RALOW/2/CD341
cells in bone marrow, cord blood, and growth factor–mobi-
lized blood represent the more immature progenitor cell sub-
set when compared with CD45RA1/CD341 cells (10),
CLA1/CD45RA1 PBPC probably constitute an already
committed cell population of only limited proliferative po-
tential (see below). Their low expression of transferrin re-
ceptors supports this assumption since the anti-CD71 reac-
tivity of a given cell usually correlates with its state of
proliferation (11).
Langerhans Cells Originate from CD341 PBPC Bearing the
Skin Homing Receptor CLA. To determine whether both
CLA1 and CLA2 PBPC can differentiate into LC, we es-
tablished a subtractive culture system that is based on the
panning of one subpopulation of PBPC (i.e., CLA1 cells)
directly in the culture well and on the transfer and subse-
quent culture of the nonadherent subtracted (i.e., CLA2)
cells. This procedure allows for excellent cell recovery in
both the panned and nonpanned (,0.1% contamination
with CLA1 cells) fractions. When the two PBPC subsets
were cultured for 2 wk with GM-CSF/TNF-a, the total
number of nucleated cells recovered from the CLA2 frac-
tion was three to five times higher than that collected from
the CLA1 subset. These differences in the multiplication
rate reflect the phenotypic and maturational differences be-
tween the precursor cells (see above).
To test the hypothesis that CLA expression is involved
in the generation of LC, immunohistochemistry was used
to search for the presence of CD1a1 and Lag-reactive cells
(8, 12). After 10 d of stimulation with GM-CSF/TNF-a,
CD1a1 dendritically shaped cells were easily detectable in
cultures from either CLA1 or CLA2 precursors. The absolute
numbers of CD1a1 cells were always higher in the cell frac-
tion originating from CLA2 precursors because these cells
showed an approximately three- to fivefold higher prolifer-
ation compared to the CLA1 fraction (data not shown).
With regard to the progeny of CLA1/CD341 PBPC,
the percentage of CD1a1 cells ranged from 12% (day 10) to
22.5% (day 18) and that of Lag1 cells from 5% (day 10) to
20% (day 18; Table 1, Fig. 2 A). Double labeling on day 18
revealed that Lag reactivity of a given cell was restricted to
the CD1a1 population (data not shown). Whereas on day
10 the percentage of Lag1 among CD1a1 cells ranged be-
tween 35–40%, z90% of CD1a1 cells gave positive Lag
immunostaining on day 18 of culture. The majority of
CD1a1/Lag1 cells tended to form clusters (Fig. 2 A) and
were dendritic in shape. Occasionally, we observed isolated
cells with a distinctive dendritic morphology devoid of Lag
reactivity (data not shown).
In sharp contrast to these findings, cells derived from
CLA2/CD341 PBPC, while containing various numbers
of CD1a1 dendritic cells (Table 1), proved to be com-
pletely Lag2 at all time points investigated (Fig. 2 B, Table 1).
These data were confirmed at the ultrastructural level. Al-
though Birbeck granules were easily detected in one third
of CD1a1 LC (5/15 cells investigated) derived from CLA1
progenitors (Fig. 3), the search for these organelles in the
CD1a1 progeny of CLA2 cells yielded negative results (data
not shown). Concerning other phenotypic features of the
CD1a1 progeny of CLA1 and CLA2 progenitors, we found
that, on day 18 of culture, CD1a1 cells derived from either
CLA1 or CLA2 progenitors uniformly expressed MHC
class II and CD80 (data not shown). CD14 was detected on
Figure 1. Distinct phenotype of CLA1 and CLA2 PBPC in normal
peripheral blood. Using three-color flow cytometry, freshly isolated
PBPC from healthy volunteers were analyzed for the distribution of the
antigens shown on the y-axis. Reactivity was measured for gated CLA1/
CD341 (black bars) and CLA-/CD341 (hatched bars) PBPC. Results of one
experiment are displayed as mean fluorescence intensity (MFI). Two ad-
ditional experiments with cells from different donors yielded similar re-
sults. The lack of anti-CD1a-reactivity was used as a negative control.1134 Skin Homing Receptor Expression on Langerhans Cell Precursors
a minor subpopulation of CLA1 PBPC–derived (15%) and
CLA2 PBPC–derived (6%) CD1a1 cells.
Other differences emerged when we investigated the func-
tional properties of the two populations. Although cells de-
rived from both CLA1 and CLA2 progenitors induced vig-
orous proliferation of allogeneic T cells at all time points
tested and, in this capacity, were 10–50 times more potent
than syngeneic monocytes (Fig. 4), they clearly differed from
Table 1. Phenotype of HPC-derived DC
% Antibody-reactive cells generated*
CD1a1
total
Lag1
total
Lag1
within CD1a1
Lag1
within CD1a2
CD341/CLA1
precursor 22.5 20.1 89.3 0
CD341/CLA2
precursor 11.7 0 0 0
Sorted CLA1 and CLA-depleted CD341 PBPC were cultured for 18 d
in the presence of GM-CSF plus TNF-a. Lag reactivity indicating the
presence of Birbeck granules was detected exclusively within CD1a1
cells derived from CD341/CLA1 precursor cells.
*Mean percentage of antibody-reactive cells calculated from three inde-
pendent immunostaining experiments.
Figure 3. Detection of Bir-
beck granules in CD1a1 cells de-
rived from CLA1 progenitors.
Representative ultramorphology
of a dendritically shaped CD1a1
LC that was generated from
CLA1 PBPC during 16 d of cul-
ture in the presence of GM-CSF
and TNF-a. Numerous trilami-
nar Birbeck granules (arrowheads)
can be easily seen in the perinu-
clear area. Original magnifica-
tion,  383,500.
Figure 2. Immunohistochemical analysis of CLA1 and CLA2 PBPC
progeny. CLA1 and CLA2 PBPC were cultured for two weeks in the
presence of GM-CSF/TNF-a and then subjected to Lag immunolabeling
using the APAAP procedure. Clustered (asterisks) as well as single (arrows)
Lag1 cells (red) were detectable within the CLA1/CD341 progeny (A).
No Lag reactivity was found within the progeny of CLA2 PBPC (B).
Original magnification, 3150.1135 Strunk et al. Brief Definitive Report
each other in their migratory properties. During the rou-
tine daily inspection of the PBPC progeny, we noticed that
cultures derived from either CLA1/CD341 or unfraction-
ated CD341 cells, but not from CLA-depleted CD341 cells,
contain a population of dendritically shaped cells which, in
contrast to their symbionts, moved continuously in the cul-
ture well. Microphotography revealed that these cells, per
minute, cover distances which were multiples of their own
diameter (Fig. 5). Since LC, upon receipt of an antigenic
(danger? [13]) signal, leave their epidermal residence and
migrate to the regional lymphoid organs (2), the migrating
DC observed in our cultures (assuming that they are CD1a1
LC) might reflect this in vivo situation and may therefore
serve as a paradigm of any peripheral non-lymphoid DC in
its transition to a terminally differentiated stimulator cell of
primary immune responses.
We were concerned that Birbeck granule formation in
the progeny of CLA1 PBPC, instead of being an intrinsic
property of this cellular subset, may have resulted from a
HECA-452–induced cross-linking of CLA epitopes. In fact,
the occurrence of a similar event has been described for
murine dendritic epidermal T cells upon stimulation with a
mitogenic anti–Thy-1 mAb (14). We consider this possi-
bility highly unlikely for several reasons: (a) we (1) and oth-
ers (15) have shown that unfractionated CD341 cells can
differentiate into Birbeck granule1 LC without engaging the
CLA molecule; (b) comparable absolute numbers of CD1a1/
Lag1 LC were generated from unfractionated or CLA-
sorted starting cell populations containing equivalent num-
bers of CLA1 cells; (c) freshly isolated, unfractionated PBPC,
when cultured in the presence or absence of the mAb
HECA-452, exhibited similar proliferation rates and Lag
frequencies upon stimulation with GM-CSF/TNF-a (data
not shown). The latter observation implies that the differ-
ences in the multiplication rate between CLA2 and CLA1/
CD341 PBPC are not due to an antiproliferative signal re-
sulting from the HECA-452–induced occupancy of CLA
epitopes but rather reflect differences in the maturation
state of the two cell populations.
At the present time, it is not known whether the CLA2
PBPC can develop/mature into CLA1 ones and, if so,
which factor(s) is (are) needed for this to occur. Also, it re-
mains to be determined whether the expression on PBPC
of HECA-452–reactive CLA and of other molecules nec-
essary for adhesion to and transmigration through micro-
vascular endothelial cells (e.g., CD49d/CD29) allows for
the homing of progenitors to the skin. The mutually non-
exclusive possibility exists that CLA expression merely re-
flects a distinct maturational stage of the progenitor cell that
renders it susceptible to stimuli favoring LC development.
In this context, recent attention has focused on TGF-b1
whose presence is apparently needed for the development
of LC in vitro (16) and in vivo (17). We are currently in-
vestigating whether the CLA1 cell population differs from
its CLA2 counterpart in the responsiveness to TGF-b1 and,
conversely, whether factors promoting the development of
lymphoid DC (e.g., relB) (18) are selectively/predomi-
nantly expressed in CLA2 PBPC and their progeny. Should
this be the case, we would conclude that the topographic
organization of the DC system is already determined at the
progenitor level.
Figure 4. MLR-stimulatory capacity of cells derived from CLA1 and
CLA2 PBPC. 3.3 3 103 cells generated in a 2-wk culture in GM-CSF/
TNF–containing medium from CLA1 ( circles) and CLA2 ( diamonds)
PBPC and, for comparison, monocytes from the same donor (squares)
were tested for their capacity to stimulate 105 allogeneic T cells. Cells
were pulsed with [3H]thymidine for 16 h after 4, 5, or 6 d of coculture.
The [3H]thymidine incorporation rate is expressed as mean cpm values
6 SD of triplicate cultures. 105 mitomycin C–treated APC or purified T
cells gave ,500 cpm. One representative experiment out of three per-
formed is shown.
Figure 5. A subpopulation of
cells derived from CLA1/CD341
PBPC exhibits a high motility in
culture. Time-lapse micropho-
tography was performed with
cells derived from CLA1 PBPC
after 3 wk of culture in the pres-
ence of GM-CSF/TNF-a. Pic-
tures of cells migrating within
the culture well were taken ev-
ery minute. One (arrowhead) of
the two dendritically shaped cells
shown (A, time point zero) cov-
ers a distance being multiples of
its own diameter within 3 min
(B). Original magnification, 3150.
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